Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

Abstract Background Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis (MS). However, it remains to be established whether certain B cell subsets are differentially repopulat...

Full description

Bibliographic Details
Main Authors: Carla Rodriguez-Mogeda, Zoë Y. G. J. van Lierop, Susanne M. A. van der Pol, Loet Coenen, Laura Hogenboom, Alwin Kamermans, Ernesto Rodriguez, Jack van Horssen, Zoé L. E. van Kempen, Bernard M. J. Uitdehaag, Charlotte E. Teunissen, Maarten E. Witte, Joep Killestein, Helga E. de Vries
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Journal of Neuroinflammation
Subjects:
Multiple sclerosis
B cells
Ocrelizumab
Online Access:https://doi.org/10.1186/s12974-023-02900-z

Internet

https://doi.org/10.1186/s12974-023-02900-z

Similar Items